Accueil>>Signaling Pathways>> Antibody-drug Conjugate/ADC Related>> ADC Linker>>Propargyl-PEG4-thiol

Propargyl-PEG4-thiol

Catalog No.GC67451

Le propargyl-PEG4-thiol est un lieur PROTAC à base de PEG qui peut être utilisé dans la synthèse des PROTAC. Le propargyl-PEG4-thiol est un lieur ADC non clivable utilisé dans la synthèse de conjugués anticorps-médicament (ADC).

Products are for research use only. Not for human use. We do not sell to patients.

Propargyl-PEG4-thiol Chemical Structure

Cas No.: 1347750-80-4

Taille Prix Stock Qté
250mg
1 131,00 $US
En stock
500mg
1 657,00 $US
En stock
1g
2 376,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com


Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Propargyl-PEG4-thiol is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Propargyl-PEG4-thiol is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs)[1].

PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker.

[1]. Goswami LN, et al. Efficient synthesis of diverse heterobifunctionalized clickable oligo(ethylene glycol) linkers: potential applications in bioconjugation and targeted drug delivery.

Avis

Review for Propargyl-PEG4-thiol

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Propargyl-PEG4-thiol

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.